# Church & Dwight Co Inc: Form 10-Q for the period ended Mar 31, 2021

- Company: [Church & Dwight Co Inc](/companies/chd.md) (CIK 313927)
- Form: 10-Q
- Filed: 2021-04-29
- Accepted by EDGAR: Apr 29, 2021, 20:12 ET
- Period: 2021-03-31
- Accession: 0001564590-21-021960
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/313927/000156459021021960/chd-10q_20210331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/313927/000156459021021960/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-01-01 to 2021-03-31 | $1.24bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-01-01 to 2021-03-31 | $688.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2021-01-01 to 2021-03-31 | $550.9m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-01-01 to 2021-03-31 | $24.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-01-01 to 2021-03-31 | $149.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-01-01 to 2021-03-31 | $302.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-01-01 to 2021-03-31 | $14.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-01-01 to 2021-03-31 | $70.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-01-01 to 2021-03-31 | $220.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-01-01 to 2021-03-31 | $0.88 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-01-01 to 2021-03-31 | $0.90 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-01-01 to 2021-03-31 | 249,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2021-01-01 to 2021-03-31 | $100.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2021-01-01 to 2021-03-31 | $26.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2021-01-01 to 2021-03-31 | $61.9m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2021-03-31 | $127.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-03-31 | $1.11bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-03-31 | $7.38bn | us-gaap:Assets |
| Current liabilities | at 2021-03-31 | $1.27bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-03-31 | $4.17bn | us-gaap:Liabilities |
| Long-term debt | at 2021-03-31 | $1.81bn | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2021-03-31 | $282.2m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2021-03-31 | $3.21bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 24,262 characters.

#### Recent Developments

#### COVID-19 Disclosure

The COVID-19 pandemic is positively impacting certain of our businesses, while negatively impacting the short-term results of certain others. For our first quarter ended March 31, 2021, we continued to experience increased demand for some of our products, including VITAFUSION and L’IL CRITTERS gummy vitamins, pregnancy test kits, women’s electric grooming, and Orajel. Some products have been negatively impacted by the temporary closures of certain non-essential retailers, the permanent closure of other retailers, and the reduction of consumer foot traffic at retailers from which these brands derive a significant proportion of sales, as well as a negative impact from ongoing social distancing measures. Overall, we have continued to experience increased online sales. We have taken steps to increase short-term manufacturing capacity for our cleaning products (including laundry detergent, baking soda, and cleaners) and health care products (including vitamins and nasal hygiene), and continue to work closely with our suppliers, contract manufacturers and retail partners to ensure sustained supply to keep pace with increased demand. We have also made investments in the expansion of long-term in-house and third-party manufacturing capacity. During the first quarter of 2021, raw material and transportation costs rose, in part due to the impact of the pandemic and the Texas freeze.

The extent of COVID-19’s effect on our operational and financial performance in the future will depend on future developments, including the duration, spread and intensity of the pandemic, the impact of vaccines, and our continued ability to manufacture and distribute our products, as well as any future government actions affecting consumers and the economy generally, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. Our priorities during the COVID-19 pandemic continue to be protecting the health and safety of our employees; maximizing the availability of products that help consumers with their health, hygiene and cleaning needs; and, using our employees’ talents and our resources to help society meet and overcome the current challenges.

For additional information on the impacts and our response to the COVID-19 pandemic and the risks that could impact our results, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

### Results of Operations

### Consolidated results

|  | Three Months Ended March 31, 2021 | Change vs. Prior Year | Three Months Ended March 31, 2020 |
| --- | ---: | ---: | ---: |
| **Net Sales** | **$1,238.9** | 6.3% | $1,165.2 |
| **Gross Profit** | **$550.9** | 3.6% | $532.0 |
| Gross Margin | **44.5%** | -120 basis points | 45.7% |
| **Marketing Expenses** | **$98.7** | 2.4% | $96.4 |
| Percent of Net Sales | **8.0%** | -30 basis points | 8.3% |
| **Selling, General & Administrative Expenses** | **$149.6** | 23.6% | $121.0 |
| Percent of Net Sales | **12.1%** | +170 basis points | 10.4% |
| **Income from Operations** | **$302.6** | -3.8% | $314.6 |
| Operating Margin | **24.4%** | -260 basis points | 27.0% |
| **Net income per share - Diluted** | **$0.88** | -4.3% | $0.92 |

Diluted Net Income per share was $0.88 in the first quarter of 2021 as compared to $0.92 in the first quarter of 2020.

During the first quarter of 2021 we decreased the fair value of our business acquisition liability associated with the 2019 acquisition of the FLAWLESS hair removal business (the “Flawless Acquisition”) by $19.0 ($14.3 after tax or $0.05 diluted per share), based on updated sales forecasts. The business acquisition liability adjustment was recorded as a reduction in SG&A expense.

During the first quarter of 2020, we reduced the fair value of our business acquisition liability by $27.0 ($20.2 after tax or $0.08 diluted per share) associated with the Flawless Acquisition based on updated sales forecasts and the passage of time. The business acquisition liability adjustment was recorded as a reduction in SG&A expense.

The Flawless business acquisition liability was reclassified to Current Liabilities in the first quarter of 2021.

Also during the first quarter of 2020, we completed the sale of the PERL WEISS® toothpaste brand in Germany which resulted in a gain of $3.0 ($2.2 after tax or $0.01 diluted per share) recorded in SG&A expense.

#### Net Sales

Net sales for the quarter ended March 31, 2021 were $1,238.9, an increase of $73.7 or 6.3% as compared to the same period in 2020. The components of the net sales increase are as follows:

| Net Sales - Consolidated | Three Months Ended March 31, 2021 |
| --- | ---: |
| Product volumes sold | 3.1% |
| Pricing/Product mix | 1.8% |
| Foreign exchange rate fluctuations | 0.9% |
| Acquired product lines (net of divestiture) (1) | 0.5% |
| **Net Sales increase** | **6.3%** |

(1) On December 1, 2020, we acquired all of the outstanding equity of Consumer Health Holdco LLC, the owner of the ZICAM™ brand and cold remedy products business (the “Zicam Acquisition”). The results of this acquisition are included in our results since the date of acquisition. During the first quarter of 2020 we completed the sale of the PERL WEISS brand.

For the three months ended March 31, 2021, the volume change reflects increased product sales in the Consumer Domestic and Consumer International segments, with volume declines in the Specialty Products (“SPD”) segment. For the three months ended March 31, 2021, price/mix was favorable in the Consumer Domestic and SPD segments, but was partially offset by unfavorable price/mix in the Consumer International segment.

#### Gross Profit / Gross Margin

Our gross profit was $550.9 for the three months ended March 31, 2021, an $18.9 increase as compared to the same period in 2020. Gross margin decreased 120 basis points (“bps”) in the first quarter of 2021 compared to the same period in 2020, due to the impact of higher manufacturing costs of 250 bps (partially due to costs associated with the COVID-19 pandemic), higher commodity and transportation costs of 200 bps, and higher costs of 40 bps as a result of incremental tariffs, partially offset by favorable price/volume/mix of 200 bps (primarily due to a reduction in trade promotion and coupons), and the impact of productivity programs of 170 bps.

#### Operating Expenses

Marketing expenses for the three months ended March 31, 2021 were $98.7, an increase of $2.3 or 2.4% as compared to the same period in 2020. The higher marketing expenses are due to investments behind new product launches, consumer research and digital advertising. Marketing expenses as a percentage of net sales in the first quarter of 2021 decreased by 30 bps to 8.0% as compared to 8.3% in the same period in 2020 due to 50 bps of leverage on higher net sales partially offset by 20 bps on higher expenses.

SG&A expenses were $149.6 in the first quarter of 2021, an increase of $28.6 or 23.6% as compared to the same period in 2020. SG&A as a percentage of net sales increased 170 bps to 12.1% in the first quarter of 2021 as compared to 10.4% in the same period in 2020. The increase is due to 230 bps on higher expenses, partially offset by 60 bps of leverage associated with higher sales. The higher expenses for the three-month period ended March 31, 2021 are primarily due to higher expense related to the Zicam Acquisition (including amortization), lower year-over-year favorable adjustments to the fair value of the Flawless business acquisition liability, higher information systems and R&D costs, and the prior year gain on the sale of PERL WEISS.

Other (income) expense, net was nominal for the three months ended March 31, 2021 and 2020.

Interest expense for the three months ended March 31, 2021 decreased $2.3 to $14.0, as compared to the same period in 2020, primarily due to lower interest rates.

#### Income Taxes

The effective tax rate for the three months ended March 31, 2021 was 24.2% compared to 23.2% in the same period in 2020. The increase in the tax rate is primarily due to a lower tax benefit related to stock option exercises.

### Segment results

We operate three reportable segments: Consumer Domestic, Consumer International and SPD. These segments are determined based on differences in the nature of products and organizational and ownership structures. We also have a Corporate segment.

| Segment | Products |
| --- | --- |
| Consumer Domestic | Household and personal care products |
| Consumer International | Primarily personal care products |
| SPD | Specialty chemical products |

The Corporate segment income consists of equity in earnings of affiliates. As of March 31, 2021, we held 50% ownership interests in each of Armand Products Company (“Armand”) and The ArmaKleen Company (“ArmaKleen”), respectively. Our equity in earnings of Armand and ArmaKleen, totaling $2.6 and $1.6 for the three months ended March 31, 2021 and 2020, respectively, are included in the Corporate segment. Certain subsidiaries that are included in the Consumer International segment manufacture and sell personal care products to the Consumer Domestic segment. These sales are eliminated from the Consumer International segment results set forth below.

Segment net sales and income before income taxes for the three months ended March 31, 2021 and March 31, 2020 are as follows:

| Net Sales(1) | Consumer Domestic | Consumer International | SPD | Corporate(3) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| **First Quarter 2021** | **$942.4** | **$216.4** | **$80.1** | **$0.0** | **$1,238.9** |
| First Quarter 2020 | 891.0 | 198.6 | 75.6 | 0.0 | 1,165.2 |
| **Income before Income Taxes(2)** |  |  |  |  |  |
| **First Quarter 2021(4)** | **$240.9** | **$38.2** | **$9.3** | **$2.6** | **$291.0** |
| First Quarter 2020(5) | 250.8 | 38.2 | 8.8 | 1.6 | 299.4 |

(1) Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table, were $2.6 and $3.0 for the three months ended March 31, 2021 and March 31, 2020, respectively.

(2) In determining income before income taxes, interest expense, investment earnings and certain aspects of other income and expense were allocated among the segments based upon each segment’s relative income from operations.

(3) Corporate segment consists of equity in earnings of affiliates from Armand and ArmaKleen for the three months ended March 31, 2021 and March 31, 2020.

(4) 2021 results include a $19.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $16.1 was recorded to Consumer Domestic and $2.9 was recorded to Consumer International.

(5) 2020 results include a $27.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $23.0 was recorded to Consumer Domestic and $4.0 was recorded to Consumer International. During 2020, we sold our PERL WEISS® toothpaste brand in Germany resulting in a reduction in SG&A expenses of $3.0 recorded in Consumer International.

Product line revenues from external customers are as follows:

|  | Three Months Ended March 31, 2021 | March 31, 2020 |
| --- | ---: | ---: |
| Household Products | **$495.2** | $494.3 |
| Personal Care Products | **447.2** | 396.7 |
| Total Consumer Domestic | **942.4** | 891.0 |
| Total Consumer International | **216.4** | 198.6 |
| Total SPD | **80.1** | 75.6 |
| **Total Consolidated Net Sales** | **$1,238.9** | $1,165.2 |

Household Products include laundry, deodorizing, and cleaning products. Personal Care Products include condoms, pregnancy kits, oral care products, skin care and hair care products and gummy dietary supplements.

### Consumer Domestic

Consumer Domestic net sales in the first quarter of 2021 were $942.4, an increase of $51.4 or 5.8% as compared to the same period in 2020. The components of the net sales change are the following:

| Net Sales - Consumer Domestic | Three Months Ended March 31, 2021 |
| --- | ---: |
| Product volumes sold | 3.3% |
| Pricing/Product mix | 1.8% |
| Acquired product lines (1) | 0.7% |
| **Net Sales increase** | **5.8%** |

(1) Includes the Zicam Acquisition since the date of acquisition.

The increase in net sales for the three months ended March 31, 2021, reflects the impact of the Zicam Acquisition, higher net sales in VITAFUSION® and L’IL CRITTERS® gummy vitamins, WATERPIK® oral care products, FLAWLESS® beauty products, ARM & HAMMER® clumping cat litter, KABOOM® bathroom cleaners, and VIVISCAL® hair thinning.

Condom usage has declined, as a result of a lower 18 to 24 year-old population, alternate birth control options, less fear of HIV, and decreased sexual activity. The decline in usage, as well as increased competition, have contributed to lower demand for our products in the condom category. Due primarily to the recent social distancing requirements related to the COVID-19 pandemic, condom usage continues to decline, although we expect the condom category will recover with the continued rollout of vaccines and a reduction of social distancing restrictions. As a result, the TROJAN business has experienced sales and profit declines that has eroded a portion of the excess between the fair and carrying value of the tradename, which could potentially result in an impairment. The carrying value of the TROJAN tradename is $176.4 and fair value exceeded carrying value by 53% as of December 31, 2020. This indefinite-lived intangible asset is susceptible to impairment risk. While management can and has implemented strategies to address the risk, including lowering our production costs, investing in new product ideas, and developing new creative advertising, significant changes in operating plans or adverse changes in the future could reduce the underlying cash flows used to estimate fair value. This could result in a decline in fair value that could trigger a future impairment charge of the tradename.

Consumer Domestic income before income taxes for the first quarter of 2021 was $240.9, a $9.9 decrease as compared to the first quarter of 2020. The decrease is due primarily to unfavorable manufacturing and distribution expenses of $30.2, higher SG&A expenses of $23.7 (partially due to lower expense from fair value adjustments to the Flawless business acquisition liability), partially offset by a $23.9 benefit from higher volumes, favorable price/mix of $16.7, lower interest and other expenses of $2.1, and lower marketing expenses of $1.5.

### Consumer International

Consumer International net sales were $216.4 in the first quarter of 2021, an increase of $17.8 or 9.0% as compared to the same period in 2020. The components of the net sales change are the following:

| Net Sales - Consumer International | Three Months Ended March 31, 2021 |
| --- | ---: |
| Product volumes sold | 3.5% |
| Pricing/Product mix | (0.3%) |
| Foreign exchange rate fluctuations | 5.8% |
| **Net Sales increase** | **9.0%** |

Excluding the impact of foreign exchange rates, higher sales in the first quarter ended March 31, 2021 were driven primarily by WATERPIK, ARM & HAMMER liquid laundry detergent, OXICLEAN®, and FEMFRESH® in the Global Markets Group, WATERPIK in Germany, and ANUSOL® in the U.K.

Consumer International income before income taxes was $38.2 in the first quarter of 2021, with no change as compared to the same period in 2020. Higher sales volumes of $4.0, favorable foreign exchange rates of $2.7, lower interest and other expense of $0.8, and favorable manufacturing and commodity costs of $0.1, were offset by higher SG&A costs of $5.5 (partially due to lower expense from fair value adjustments to the Flawless business acquisition liability), higher marketing expenses of $2.0, and unfavorable price/product mix of $0.1.

### Specialty Products (“SPD”)

SPD net sales were $80.1 in the first quarter of 2021, an increase of $4.5 or 6.0% as compared to the same period in 2020. The components of the net sales change are the following:

| Net Sales - SPD | Three Months Ended March 31, 2021 |
| --- | ---: |
| Product volumes sold | (1.6%) |
| Pricing/Product mix | 7.6% |
| **Net Sales increase** | **6.0%** |

25

Net sales increased due to higher pricing in the dairy market, partially offset by lower volume.

SPD income before income taxes was $9.3 in the first quarter of 2021, an increase of $0.5 as compared to the same period in 2020, due primarily to favorable price/product mix of $5.7, and lower SG&A costs of $0.5, partially offset by unfavorable manufacturing costs of $4.7, lower sales volumes of $1.0, and higher marketing expenses of $0.1.

### Corporate

The Corporate segment includes equity in earnings of affiliates from Armand and ArmaKleen in the first quarter of 2021 and 2020. The Corporate segment income before income taxes was $2.6 in the first quarter of 2021, as compared to $1.6 in the same period in 2020.

### Liquidity and Capital Resources

On May 1, 2019, we amended the credit agreement (the “Credit Agreement”) that provides for our $1,000.0 unsecured revolving credit facility (the “Revolving Credit Facility”) to extend the term of the Revolving Credit Facility from March 29, 2023 to March 29, 2024. We continue to have the ability to increase our borrowing up to an additional $600.0, subject to lender commitments and certain conditions as described in the Credit Agreement. Borrowings under the Credit Agreement are available for general corporate purposes.

As of March 31, 2021, we had $127.5 in cash and cash equivalents, and approximately $717.0 available through the Revolving Credit Facility and our commercial paper program. To preserve our liquidity, we invest cash primarily in government money market funds, prime money market funds, short-term commercial paper and short-term bank deposits.

The current economic environment presents risks that could have adverse consequences for our liquidity. See “Unfavorable economic conditions could adversely affect demand for our products” under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Form 10-K”). Although there is uncertainty related to the impact of the COVID-19 pandemic on our future results, we believe our efficient business model and strong balance sheet position us to manage our business through this crisis. We continue to manage all aspects of our business including, but not limited to, monitoring the financial health of our customers, suppliers and other third-party relationships, implementing gross margin enhancement strategies and developing new opportunities for growth. We do not anticipate that current economic conditions will adversely affect our ability to comply with the financial covenant in the Credit Agreement because we currently are, and anticipate that we will continue to be, in compliance with the maximum leverage ratio requirement under the Credit Agreement.

On January 29, 2021, the Board declared a 5.2% increase in the regular quarterly dividend from $0.24 to $0.2525 per share, equivalent to an annual dividend of $1.01 per share payable to stockholders of record as of February 16, 2021. The increase raises the annual dividend payout from $237.0 to approximately $250.0.

In December 2020, we entered into an accelerated share repurchase (“ASR”) contract with a commercial bank to purchase Common Stock. We paid $300.0 to the bank, inclusive of fees, and received an initial delivery of shares equal to $270.0, or 3.1 million shares. We used cash on hand and short-term borrowings to fund the initial purchase price. Upon the completion of the ASR, which ended in February 2021, the bank delivered to us an additional 0.4 million shares. The final shares delivered to us were determined by the average price per share paid by the bank during the purchase period. All 3.5 million shares were purchased under our evergreen stock repurchase program.

There remains $210.0 of the initial $500.0 of share repurchase availability under our share repurchase plan approved by the Board of Directors on November 1, 2017 (the “2017 Share Repurchase Program”) as of March 31, 2021.

We anticipate that our cash from operations, together with our current borrowing capacity, will be sufficient to fund our share repurchase programs to the extent implemented by management, pay debt and interest as it comes due and pay dividends at the latest approved rate, and meet our capital expenditure program costs, which are expected to be approximately $140 in 2021 primarily for manufacturing capacity investments in laundry, litter and vitamins to support expected future sales growth. We do not have any mandatory fixed rate debt principal payments due in 2021. Cash, together with our current borrowing capacity, may be used for acquisitions that would complement our existing product lines or geographic markets.

#### Cash Flow Analysis

|  | Three Months Ended March 31, 2021 | March 31, 2020 |
| --- | ---: | ---: |
| Net cash provided by operating activities | **$100.2** | $236.5 |
| Net cash used in investing activities | **$(30.0)** | $(11.4) |
| Net cash (used in) provided by financing activities | **$(125.0)** | $670.1 |

27

**Net Cash Provided by Operating Activities –** Our primary source of liquidity is the cash flow provided by operating activities, which is dependent on net income and changes in working capital. Our net cash provided by operating activities in the first three months ended March 31, 2021 decreased by $136.3 to $100.2 as compared to $236.5 in the same period in 2020 due to an increase in working capital partially offset by higher cash earnings (net income adjusted for non-cash items such as depreciation, amortization, non-cash compensation and changes in business acquisition liabilities and deferred taxes). The change in working capital is primarily due to higher inventories, to support expected sales growth, and higher accounts receivable primarily related to the timing of sales along with lower accounts payable and accrued expenses. We measure working capital effectiveness based on our cash conversion cycle. The following table presents our cash conversion cycle information for the quarters ended March 31, 2021 and 2020:

|  | As of March 31, 2021 | March 31, 2020 | Change |
| --- | ---: | ---: | ---: |
| Days of sales outstanding in accounts receivable ("DSO") | **29** | 27 | 2 |
| Days of inventory outstanding ("DIO") | **68** | 58 | 10 |
| Days of accounts payable outstanding ("DPO") | **74** | 66 | (8) |
| Cash conversion cycle | **23** | 19 | 4 |

Our cash conversion cycle (defined as the sum of DSO and DIO less DPO) which is calculated using a two-period average method, increased 4 days from the prior year due to higher inventory to support expected sales growth and higher accounts receivable primarily related to the timing of sales, partially offset by lower accounts payable outstanding due to the timing of payments. The increase in the cash conversion cycle is primarily due to building inventory to support expected sales growth. We continue to focus on reducing our working capital requirements.

**Net Cash Used in Investing Activities –** Net cash used in investing activities during the first three months of 2021 was $30.0, primarily reflecting $26.3 for property, plant and equipment additions. Net cash used in investing activities during the first three months of 2020 was $11.4, primarily reflecting $16.8 for property, plant and equipment additions, partially offset by cash proceeds of $7.0 from the sale of the PERL WEISS® toothpaste brand in Germany.

**Net Cash (Used in) Provided by Financing Activities –** Net cash used in financing activities during the first three months of 2021 was $125.0, reflecting $69.0 of net debt payments and $61.9 of cash dividend payments, partially offset by $5.9 of proceeds from stock option exercises. Net cash provided by financing activities during the first three months of 2020 was $670.1, reflecting $719.9 of net debt borrowings and $9.3 of proceeds from stock option exercises, partially offset by $59.0 of cash dividend payments.

## Market risk

As filed, 205 characters.

### Market risk

For quantitative and qualitative disclosures about market risk affecting the Company, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 7A of Part II in the Form 10-K.

## Controls and procedures

As filed, 7,446 characters.

a) Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this report, are effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the rules and forms of the United States Securities and Exchange Commission (the “Commission”), and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding the disclosure.

b) Change in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurring during the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

### CAUTIONARY NOTE ON FORWARD-LOOKING INFORMATION

This report contains forward-looking statements, including, among others, statements relating to net sales and earnings growth; the impact of the COVID-19 pandemic and the Company’s response; gross margin changes; trade and marketing spending; marketing expense as a percentage of net sales; sufficiency of cash flows from operations; earnings per share; the impact of new accounting pronouncements; cost savings programs; consumer demand and spending; the effects of competition; the effect of product mix; volume growth, including the effects of new product launches into new and existing categories; the decline of condom usage; the Company’s hedge programs; the impact of foreign exchange, tariffs, and commodity price fluctuations; impairments and other charges; the Company’s investments in joint ventures; the impact of acquisitions and divestitures; capital expenditures; the Company’s effective tax rate; the impact of tax audits; tax changes and the lapse of applicable statutes of limitations; the effect of the credit environment on the Company’s liquidity and capital resources; the Company’s fixed rate debt; compliance with covenants under the Company’s debt instruments; the Company’s commercial paper program; the Company’s current and anticipated future borrowing capacity to meet capital expenditure program costs; and the Company’s share repurchase programs; payment of dividends; environmental and regulatory matters; the availability and adequacy of raw materials, including trona reserves and the conversion of such reserves; and the customers and consumer acceptance of certain ingredients in our products. Other forward-looking statements in this report are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. These statements represent the intentions, plans, expectations and beliefs of the Company, and are based on assumptions that the Company believes are reasonable but may prove to be incorrect. In addition, these statements are subject to risks, uncertainties and other factors, many of which are outside the Company’s control and could cause actual results to differ materially from such forward-looking statements. Factors that could cause such differences include a decline in market growth, retailer distribution and consumer demand (as a result of, among other things, political, economic and marketplace conditions and events), including those relating to the outbreak of contagious diseases; other impacts of the COVID-19 pandemic and its impact on the Company’s operations, customers, suppliers, employees, and other constituents, and market volatility and impact on the economy (including causing recessionary conditions), resulting from global, nationwide or local or regional outbreaks or increases in infections, and the risk that the Company will not be able to successfully execute its response plans with respect to the pandemic or localized outbreaks and the corresponding uncertainty; the impact of regulatory changes or policies associated with the COVID-19 pandemic, including continuing or renewed shutdowns of retail and other businesses in various jurisdictions; the impact of the CARES Act and other governmental actions; the impact of continued shifts in consumer behavior, including accelerating shifts to online shopping; unanticipated increases in raw material and energy prices; delays or other problems in manufacturing or distribution; increases in transportation costs; the impact of inclement weather on raw material and transportation costs; adverse developments affecting the financial condition of major customers and suppliers; competition; changes in marketing and promotional spending; growth or declines in various product categories and the impact of customer actions in response to changes in consumer demand and the economy, including increasing shelf space or on line share of private label and retailer-branded products or other changes in the retail environment; consumer and competitor reaction to, and customer acceptance of, new product introductions and features; the Company’s ability to maintain product quality and characteristics at a level acceptable to our customers and consumers; disruptions in the banking system and financial markets; foreign currency exchange rate fluctuations; implications of the United Kingdom’s withdrawal from the European Union; shifting economic policies in the United States; potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs, including the actual and potential effect of tariffs on Chinese goods imposed by the United States; increased or changing regulation regarding the Company’s products in the United States and other countries where it or its suppliers operate; market volatility; issues relating to the Company’s information technology and controls; the impact of natural disasters, including those related to climate change, on the Company and its customers and suppliers, including third party information technology service providers; the acquisition or divestiture of assets; the outcome of contingencies, including litigation, pending regulatory proceedings and environmental matters; and changes in the regulatory environment.

The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the United States federal securities laws. You are advised, however, to consult any further disclosures the Company makes on related subjects in its filings with the United States Securities and Exchange Commission (the “Commission”).

## Risk factors

As filed, 252 characters.

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Item 1A, “Risk Factors” in the Form 10-K, which could materially affect the Company’s business, financial condition or future results.

Filed Apr 29, 2021.
Source: SEC EDGAR, the filing index for accession 0001564590-21-021960. Last ingested by Listed: Nov 14, 2026, 21:34 ET. No prices; not investment advice.
